BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

661 related articles for article (PubMed ID: 21484570)

  • 21. Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease.
    Walker BR; Andrew R
    Ann N Y Acad Sci; 2006 Nov; 1083():165-84. PubMed ID: 17148739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 11 beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
    Wake DJ; Walker BR
    Mol Cell Endocrinol; 2004 Feb; 215(1-2):45-54. PubMed ID: 15026174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 11-Dehydrocorticosterone causes metabolic syndrome, which is prevented when 11β-HSD1 is knocked out in livers of male mice.
    Harno E; Cottrell EC; Keevil BG; DeSchoolmeester J; Bohlooly-Y M; Andersén H; Turnbull AV; Leighton B; White A
    Endocrinology; 2013 Oct; 154(10):3599-609. PubMed ID: 23832962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of disease: Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome.
    Tomlinson JW; Stewart PM
    Nat Clin Pract Endocrinol Metab; 2005 Dec; 1(2):92-9. PubMed ID: 16929377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 11β-Hydroxysteroid dehydrogenase type 1 inhibition in type 2 diabetes mellitus.
    Hollis G; Huber R
    Diabetes Obes Metab; 2011 Jan; 13(1):1-6. PubMed ID: 21114597
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 2-amino-1,3-thiazol-4(5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice.
    Johansson L; Fotsch C; Bartberger MD; Castro VM; Chen M; Emery M; Gustafsson S; Hale C; Hickman D; Homan E; Jordan SR; Komorowski R; Li A; McRae K; Moniz G; Matsumoto G; Orihuela C; Palm G; Veniant M; Wang M; Williams M; Zhang J
    J Med Chem; 2008 May; 51(10):2933-43. PubMed ID: 18419108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action.
    Draper N; Stewart PM
    J Endocrinol; 2005 Aug; 186(2):251-71. PubMed ID: 16079253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease.
    Morton NM
    Mol Cell Endocrinol; 2010 Mar; 316(2):154-64. PubMed ID: 19804814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role and regulation of 11β-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
    Stimson RH; Walker BR
    Horm Mol Biol Clin Investig; 2013 Sep; 15(2):37-48. PubMed ID: 25436731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone (KR-66344).
    Park JS; Rhee SD; Kang NS; Jung WH; Kim HY; Kim JH; Kang SK; Cheon HG; Ahn JH; Kim KY
    Biochem Pharmacol; 2011 Apr; 81(8):1028-35. PubMed ID: 21315688
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice.
    Hermanowski-Vosatka A; Balkovec JM; Cheng K; Chen HY; Hernandez M; Koo GC; Le Grand CB; Li Z; Metzger JM; Mundt SS; Noonan H; Nunes CN; Olson SH; Pikounis B; Ren N; Robertson N; Schaeffer JM; Shah K; Springer MS; Strack AM; Strowski M; Wu K; Wu T; Xiao J; Zhang BB; Wright SD; Thieringer R
    J Exp Med; 2005 Aug; 202(4):517-27. PubMed ID: 16103409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes.
    Gathercole LL; Stewart PM
    J Steroid Biochem Mol Biol; 2010 Oct; 122(1-3):21-7. PubMed ID: 20347978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Time of the day for 11beta-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice.
    Véniant MM; Hale C; Komorowski R; Chen MM; St Jean DJ; Fotsch C; Wang M
    Diabetes Obes Metab; 2009 Feb; 11(2):109-17. PubMed ID: 18479468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Active site variability of type 1 11beta-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons.
    Hult M; Shafqat N; Elleby B; Mitschke D; Svensson S; Forsgren M; Barf T; Vallgårda J; Abrahmsen L; Oppermann U
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):26-33. PubMed ID: 16431016
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue.
    Apostolova G; Schweizer RA; Balazs Z; Kostadinova RM; Odermatt A
    Am J Physiol Endocrinol Metab; 2005 May; 288(5):E957-64. PubMed ID: 15613680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning.
    Walker BR
    Proc Nutr Soc; 2007 Feb; 66(1):1-8. PubMed ID: 17343766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bezafibrate regulates the expression and enzyme activity of 11beta-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes.
    Nakano S; Inada Y; Masuzaki H; Tanaka T; Yasue S; Ishii T; Arai N; Ebihara K; Hosoda K; Maruyama K; Yamazaki Y; Shibata N; Nakao K
    Am J Physiol Endocrinol Metab; 2007 Apr; 292(4):E1213-22. PubMed ID: 17190905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors with oleanan and ursan scaffolds.
    Blum A; Favia AD; Maser E
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):132-6. PubMed ID: 18822345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cell-based assay for screening 11beta-hydroxysteroid dehydrogenase 1 inhibitors.
    Cho YS; Kim CH; Cheon HG
    Anal Biochem; 2009 Sep; 392(2):110-6. PubMed ID: 19497289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIS-388, a novel orally active and long-acting 11β-hydroxysteroid dehydrogenase type 1 inhibitor, ameliorates insulin sensitivity and glucose intolerance in diet-induced obesity and nongenetic type 2 diabetic murine models.
    Okazaki S; Takahashi T; Iwamura T; Nakaki J; Sekiya Y; Yagi M; Kumagai H; Sato M; Sakami S; Nitta A; Kawai K; Kainoh M
    J Pharmacol Exp Ther; 2014 Oct; 351(1):181-9. PubMed ID: 25100752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.